Hydrocortisone
(Synonyms: 氢化可的松; Cortisol) 目录号 : GC11551
A glucocorticoid
Cas No.:50-23-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
The human umbilical cord vein cell line EA.hy.926 |
|
Preparation Method |
DHA at 0.1, 1 and 10µM, hydrocortisone at 0.5µg/mL or vehicle control. After 24h incubation with the pre-treatment, cells were challenged with recombinant human TNFα (50ng/ml) and IL-1β (10ng/mL). |
|
Reaction Conditions |
0.5µg/mL for 24 hours |
|
Applications |
In the same inflammatory conditions, pre-treatment with hydrocortisone induced a return to baseline, whereas DHA induced an increase of DHA-derived oxylipins that remains subtle at 0,1 and 1 µM, to reach more than half of the total oxylipin output at 10 µM. |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6 mice |
|
Preparation Method |
In the hydrocortisone group, mice were subcutaneously injected with 1.5 mg/kg hydrocortisone at 1 h after sepsis induction. |
|
Dosage form |
Subcutaneously injection, 1.5 mg/kg |
|
Applications |
Model mice were treated with hydrocortisone at 1 h after sepsis induction. After 12 h, the kidney tissue and blood samples were collected. After CLP, the kidney function biomarkers SCR and BUN were significantly elevated in the blood sample of mice, but this elevation was blocked by hydrocortisone treatment. |
|
References: [1]: A.C.Mottaa. K.Strassburg. P.Oranjea, R.J.Vreekenbc, D.M.Jacobsa, et al. Oxylipin profiling in endothelial cells in vitro - Effects of DHA and hydrocortisone upon an inflammatory challenge. 2019. Prostaglandins & Other Lipid Mediators. 144.doi. org/10.1016/j.prostaglandins.2019.106352 |
|
Hydrocortisone, a natural glucocorticoid secreted by adrenal and extra-adrenal tissues, locally governs the transcription of genes involved in inflammation, immune response, metabolism, and energy homeostasis via binding to its cognate glucocorticoid receptor (GR) [1]. Glucocorticoids as hydrocortisone and methylprednisolone are known as ABCB1 substrates [2].
Hydrocortisone was observed to significantly decrease co-culture-induced pp38 MAPK expression in bothpancreatic acinar cells (PACs) and stellate cells (PSCs). The 10 nM concentration of hydrocortisone used in the study was significantly lower than the lowest normal serum cortisol level of approximately 140 nM in human sera [3].
The Hydrocortisone treatment alleviates sepsis-induced acute kidney injury in mice through HSF-1-mediated transcriptional suppression of XPO1 [4]. Hydrocortisone (70, 140 or 200 mg/kg) treated mice with i.p. injection of did not change either number or percentage of bone marrow B cell subsets. After 24 h of a single i.p. injection of 140 mg/kg of hydrocortisone a reduction in thymus weight and number of thymocytes could be observed. When mice were i.p. injected with hydrocortisone for three consecutive days, there was a depletion of the percentage and number of progenitors and lymphocytes [2].
References:
[1]. Sridharan, K., Rathore, B., Yousuf, M., Reddy Rachamalla, H. K., Jinka, S., Jaggarapu, M. M. C. S., & Banerjee, R. (2021). Self-assembling derivative of hydrocortisone as glucocorticoid receptor-targeted nanotherapeutics for synergistic, combination therapy against colorectal tumor. Molecular Pharmaceutics, 18(3), 1208- 1228.
[2]. Costa K.M.D, Valente R.C, Silva J.M.C.D, Paiva L.S, Rumjanek V.M, Glucocorticoid susceptibility and in vivo ABCB1 activity differ in murine B cell subsets. An. Acad. Bras. Cienc. 2018; 90 (30304236): 3081-3097. 10.1590/0001-3765201820180364
[3]. BlÄuer, M.; Sand, J.; Laukkarinen, J. Regulation of p38 MAPK and glucocorticoid receptor activation by hydrocortisone in mono-and co-cultured pancreatic acinar and stellate cells. Pancreatology 2021, 21, 384-389.
[4]. L Jin, W Liao, X Zhou, Y Wang, J Qian, et al. Hydrocortisone alleviates sepsis-induced acute kidney injury through HSF-1-mediated transcriptional suppression of XPO1. Tissue and Cell. 2022. 79. doi.org/10.1016/j.tice.2022.101915.
氢化可的松是一种由肾上腺和肾上腺外组织分泌的天然糖皮质激素，通过与其同源糖皮质激素受体 (GR) 结合，局部控制参与炎症、免疫反应、新陈代谢和能量稳态的基因的转录 [1 ]。糖皮质激素如氢化可的松和甲泼尼龙被称为 ABCB1 底物[2]。
观察到氢化可的松显着降低共培养诱导的胰腺腺泡细胞 (PAC) 和胰腺腺泡细胞 (PAC) 中的 pp38 MAPK 表达。星状细胞 (PSC)。研究中使用的 10 nM 氢化可的松浓度显着低于人血清中约 140 nM 的最低正常血清皮质醇水平 [3]。
氢化可的松治疗可减轻败血症- 通过 HSF-1 介导的 XPO1 转录抑制诱导小鼠急性肾损伤 [4]。氢化可的松（70、140 或 200 mg/kg）用 i.p. 处理小鼠。注射不会改变骨髓 B 细胞亚群的数量或百分比。单次 i.p. 24 小时后。注射 140 mg/kg 氢化可的松可观察到胸腺重量和胸腺细胞数量减少。当老鼠被 i.p.连续三天注射氢化可的松后，祖细胞和淋巴细胞的百分比和数量均有下降[2]。
| Cas No. | 50-23-7 | SDF | |
| 别名 | 氢化可的松; Cortisol | ||
| 化学名 | (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one | ||
| Canonical SMILES | CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O | ||
| 分子式 | C21H30O5 | 分子量 | 362.46 |
| 溶解度 | ≥ 13.3mg/mL in DMSO | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7589 mL | 13.7946 mL | 27.5893 mL |
| 5 mM | 0.5518 mL | 2.7589 mL | 5.5179 mL |
| 10 mM | 0.2759 mL | 1.3795 mL | 2.7589 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Hydrocortisone aceponate
Hydrocortisone Dosing for Hypotension in Newborn Infants: Less Is More
Hydrocortisone-colestipol interaction
'Hydrocortisone alcohol'
Immediate-release granule formulation of hydrocortisone, Alkindi?, for treatment of paediatric adrenal insufficiency (Infacort development programme)
Treatment of paediatric patients with adrenal insufficiency is challenging due to the lack of appropriate glucocorticoid preparations for children, and the use of either pharmacy- or parent-compounded hydrocortisone tablets. Alkindi (hydrocortisone granules in capsules for opening) is a new therapeutic option for paediatric adrenal insufficiency. Areas Covered: Drawbacks of current therapy and formulation and clinical trial programme for Alkindi. Expert Commentary: Compounding hydrocortisone has multiple issues including inconsistent dosing with under and over treatment and practical problems for parents who compound the drug themselves or travel long distances to a compounding pharmacy and the cost of compounding by the pharmacy. Alkindi? is a novel paediatric formulation of immediate release hydrocortisone licensed for use in paediatric adrenal insufficiency. Alkindi? is formulated to address the needs of neonates, infants and young children, being available at appropriate paediatric doses of 0.5, 1.0, 2.0 and 5.0 mg, is multiparticulate, allowing either direct oral dosing or dosing mixed with food, is taste masked to obscure the bitter taste of hydrocortisone and is bioequivalent to current hydrocortisone preparations. Clinical trials in young children with adrenal insufficiency demonstrated cortisol levels after dosing similar to those seen in healthy children and the drug was well tolerated and favoured over current therapy by parents. Alkindi? will provide a licenced treatment option for accurate dosing in children with adrenal insufficiency where compounded adult tablets of hydrocortisone are unsuitable.